[
  {
    "ts": null,
    "headline": "Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.",
    "summary": "The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.",
    "url": "https://finnhub.io/api/news?id=8b5d9a7a8877330f2718e060c2160c257457621695bd6104cab575f4ca586748",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760383440,
      "headline": "Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.",
      "id": 137070483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.",
      "url": "https://finnhub.io/api/news?id=8b5d9a7a8877330f2718e060c2160c257457621695bd6104cab575f4ca586748"
    }
  },
  {
    "ts": null,
    "headline": "New US biotech hubs showing potential amid onshoring request",
    "summary": "While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.",
    "url": "https://finnhub.io/api/news?id=de77e07e9f38aa41868ba917d2e511b15e0cd2fbbb726d8aed94105baf42138a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760367424,
      "headline": "New US biotech hubs showing potential amid onshoring request",
      "id": 137068535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.",
      "url": "https://finnhub.io/api/news?id=de77e07e9f38aa41868ba917d2e511b15e0cd2fbbb726d8aed94105baf42138a"
    }
  },
  {
    "ts": null,
    "headline": "Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?",
    "summary": "Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.",
    "url": "https://finnhub.io/api/news?id=ef762e4ac9ad23b2bd05e967bcc404955b7a954764849bcc1d9880220428e752",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760359800,
      "headline": "Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?",
      "id": 137068824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.",
      "url": "https://finnhub.io/api/news?id=ef762e4ac9ad23b2bd05e967bcc404955b7a954764849bcc1d9880220428e752"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types",
    "summary": "PRINCETON, N.J., October 13, 2025--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types",
    "url": "https://finnhub.io/api/news?id=86a6d21a89ae8c6787192ab1b7836bdcdac1356c24298ea8398aa06952554ed3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760353140,
      "headline": "Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types",
      "id": 137066454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., October 13, 2025--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types",
      "url": "https://finnhub.io/api/news?id=86a6d21a89ae8c6787192ab1b7836bdcdac1356c24298ea8398aa06952554ed3"
    }
  },
  {
    "ts": null,
    "headline": "SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration",
    "summary": "SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs. This milestone triggered a one-time payment of $250 million by Bristol Myers Squibb (NYSE: BMY), pursuant to the 2023 collaboration and exclusive license agreement between SystImmune",
    "url": "https://finnhub.io/api/news?id=68aca96b23e0bc2ec60e3d45a26006081fdab57644473a22cc3ae451a08e3305",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760346000,
      "headline": "SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration",
      "id": 137066455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs. This milestone triggered a one-time payment of $250 million by Bristol Myers Squibb (NYSE: BMY), pursuant to the 2023 collaboration and exclusive license agreement between SystImmune",
      "url": "https://finnhub.io/api/news?id=68aca96b23e0bc2ec60e3d45a26006081fdab57644473a22cc3ae451a08e3305"
    }
  },
  {
    "ts": null,
    "headline": "Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics",
    "summary": "Bristol Myers Squibb is pivoting from small-molecule drugs to mRNA and gene therapies. Click here to read more about BMY stock and why it is a Buy.",
    "url": "https://finnhub.io/api/news?id=c02384048677c173c8a0ec1d62ee49047a2d713de34ed8e34023080fd703275f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760340626,
      "headline": "Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics",
      "id": 137065920,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol Myers Squibb is pivoting from small-molecule drugs to mRNA and gene therapies. Click here to read more about BMY stock and why it is a Buy.",
      "url": "https://finnhub.io/api/news?id=c02384048677c173c8a0ec1d62ee49047a2d713de34ed8e34023080fd703275f"
    }
  }
]